FDA Determines Regulatory Review Period for RESTYLANE Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for RESTYLANE, a medical device, in accordance with federal regulations, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.